Stock A003220 DAEWON PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Daewon Pharmaceutical Co., Ltd.

Equities

A003220

KR7003220001

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 27/05/2024 BST 		5-day change 1st Jan Change
14,660 KRW 0.00% Intraday chart for Daewon Pharmaceutical Co., Ltd. -1.87% -6.39%
03-14 Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 SD Biotechnologies Co., Ltd. announced that it has received KRW 65 billion in funding from Koino Co.Ltd., Focus Asset Management Co., Ltd., Daewon Pharmaceutical Co., Ltd. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 335,002 380,715 342,999 393,197 331,930 310,734 - -
Enterprise Value (EV) 2 366.2 380.7 343 465.9 447.1 353.4 329.4 310.7
P/E ratio 11.9 x - 47.7 x 12.7 x 14.1 x 9.52 x 7.83 x 6.69 x
Yield 1.55% - 1.24% 1.07% 1.92% 2.05% 2.27% 2.05%
Capitalization / Revenue 1.05 x 1.23 x 0.97 x 0.82 x 0.63 x 0.5 x 0.49 x 0.43 x
EV / Revenue 1.15 x 1.23 x 0.97 x 0.97 x 0.85 x 0.56 x 0.52 x 0.43 x
EV / EBITDA 8.28 x - 9.21 x 7.47 x 8.98 x 5.2 x 4.65 x 3.88 x
EV / FCF 46.9 x - - 18.4 x 11.3 x 10.7 x 6.22 x 5.45 x
FCF Yield 2.13% - - 5.43% 8.82% 9.34% 16.1% 18.3%
Price to Book 1.61 x - 1.52 x 1.57 x 1.31 x 1.17 x 1.04 x 0.87 x
Nbr of stocks (in thousands) 21,571 21,224 21,219 20,971 21,196 21,196 - -
Reference price 3 15,530 17,938 16,165 18,750 15,660 14,660 14,660 14,660
Announcement Date 12/03/20 04/02/21 10/02/22 09/02/23 14/03/24 - - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 317.8 308.5 354.2 478.9 527 627.1 629.6 722
EBITDA 1 44.22 - 37.23 62.37 49.79 68 70.87 80
EBIT 1 35.11 - 19.46 43.01 32.23 51.1 53.37 63
Operating Margin 11.05% - 5.5% 8.98% 6.12% 8.15% 8.48% 8.73%
Earnings before Tax (EBT) 1 35.37 - 17.18 38.14 25.83 41 48.9 60
Net income 1 27.29 18.62 6.654 31.28 23.92 33.93 41.1 48
Net margin 8.59% 6.03% 1.88% 6.53% 4.54% 5.41% 6.53% 6.65%
EPS 2 1,303 - 339.0 1,479 1,110 1,540 1,873 2,192
Free Cash Flow 3 7,801 - - 25,317 39,446 33,000 53,000 57,000
FCF margin 2,454.39% - - 5,286.74% 7,485.61% 5,262.32% 8,418.49% 7,894.74%
FCF Conversion (EBITDA) 17,640.33% - - 40,589.36% 79,218.29% 48,529.41% 74,788.33% 71,250%
FCF Conversion (Net income) 28,585.66% - - 80,925.81% 164,927.38% 97,249.52% 128,953.77% 118,750%
Dividend per Share 2 240.4 - 200.0 200.0 300.0 300.0 333.3 300.0
Announcement Date 12/03/20 04/02/21 10/02/22 09/02/23 14/03/24 - - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - 117 122.2 122.5 124.1 133 129 140.9 158.3 155.6 148.2 164.9
EBITDA - - - - - - - - - - - -
EBIT 1 - 10.19 14.58 4.309 8.979 10.06 6.742 6.451 14.98 12.1 10.6 13.4
Operating Margin - 8.71% 11.93% 3.52% 7.24% 7.56% 5.23% 4.58% 9.46% 7.78% 7.15% 8.13%
Earnings before Tax (EBT) - - - - - - - - - - - -
Net income 1 10.51 7.402 11.07 - - - 5.456 0.7494 - 7.2 6.4 9.9
Net margin - 6.32% 9.06% - - - 4.23% 0.53% - 4.63% 4.32% 6%
EPS 495.0 - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - -
Announcement Date 16/05/22 16/08/22 11/11/22 09/02/23 15/05/23 11/08/23 14/11/23 14/03/24 16/05/24 - - -
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 31.2 - - 72.7 115 42.7 18.7 -
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 0.7056 x - - 1.165 x 2.312 x 0.6279 x 0.2639 x -
Free Cash Flow 2 7,801 - - 25,317 39,446 33,000 53,000 57,000
ROE (net income / shareholders' equity) 14.1% - 3.09% 12.9% 9.25% 11.8% 13% 13.8%
ROA (Net income/ Total Assets) 9.05% - 1.83% 7.08% 4.97% 6.5% 7.37% 7.9%
Assets 1 301.7 - 364 441.6 480.8 522.1 557.9 607.6
Book Value Per Share 3 9,637 - 10,645 11,967 11,996 12,532 14,054 16,798
Cash Flow per Share 1,949 - 1,088 1,523 - - - -
Capex 1 33 - 4.1 8.01 12.3 12.8 13.3 15
Capex / Sales 10.39% - 1.16% 1.67% 2.33% 2.04% 2.11% 2.08%
Announcement Date 12/03/20 04/02/21 10/02/22 09/02/23 14/03/24 - - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Daewon Pharmaceutical Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
14,660 KRW
Average target price
21,000 KRW
Spread / Average Target
+43.25%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
DAEWON PHARMACEUTICAL CO., LTD. Stock Daewon Pharmaceutical Co., Ltd.
-6.39% 229M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.59% 727B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.89% 347B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.66% 319B
ABBVIE INC. Stock AbbVie Inc.
+0.24% 274B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.08% 238B
NOVARTIS AG Stock Novartis AG
+7.02% 204B
ROCHE HOLDING AG Stock Roche Holding AG
-5.73% 203B
AMGEN INC. Stock Amgen Inc.
+4.23% 161B
PFIZER, INC. Stock Pfizer, Inc.
-1.70% 160B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A003220 Stock
  4. Financials Daewon Pharmaceutical Co., Ltd.